Management Of Open-angle Glaucoma Research Articles

Response to Letter to the Editor: The Use of Cost-effectiveness Analyses in Open-Angle Glaucoma Management: A Systematic Review of the Current Literature.

Response to Letter to the Editor: The Use of Cost-effectiveness Analyses in Open-Angle Glaucoma Management: A Systematic Review of the Current Literature.

Efficacy and safety of ab-externo radiofrequency sclerostomy in management of open-angle glaucoma

Purpose. To evaluate the efficacy and safety profile of an innovative ab-externo technique in the management of uncontrolled open angle glaucoma (OAG) through creating filtering tracts subconjunctivally.Material and methods. This is a randomized clinical trial including 40 eyes (40 patients) divided into 2 equal groups, group (A), underwent ab-externo radiofrequency sclerostomy and group (B), underwent ab-externo radiofrequency sclerostomy with subconjunctival injection of mitomycin C. Intraoperative and postoperative complications, visual acuity, intraocular pressure (IOP) and bleb status were evaluated for 6 months.Results. The mean preoperative IOP was 28 ± 3.5 mm Hg reduced to 21.9 ± 5.2 mm Hg (p = 0.001) in group (A) and was 29.4 ± 3.4 mm Hg reduced to 20.8 ± 6.3 mm Hg (p = 0.001) in group (B), 6 months postoperatively. Both groups showed a significant percent reduction of IOP 15.1 ± 17.3%, 27.1 ± 22.4% in groups (A) and (B) respectively with group (B) showing lower values on days 1, 7, 14, 30, 90 and 180 but was not statistically significant. The number of anti-glaucoma medications was significantly reduced in both groups. Heat radiation to the cornea from radiofrequency waves was obvious in early cases — 5 (25%) in group (A), and 3 (15%) in group (B) that was reversible within the first 3 months postoperatively. Shallow anterior chamber and choroidal detachment were the most encountered early postoperative complication, which all managed conservatively.Conclusion. Ab-externo radiofrequency sclerostomy offers a promising minimally invasive, quick and simple procedure in management of early and moderate cases of OAG with effective reduction of IOP and number of glaucoma medication.

Long-term outcome of stab incision glaucoma surgery versus trabeculectomy surgery in the management of primary open angle glaucoma

Purpose To assess the long-term outcome of Stab incision glaucoma surgery (SIGS) and compare it with subscleral trabeculectomy (SST) in the management of open-angle glaucoma (OAG). Methods Twenty eyes of 20 OAG patients were randomly assigned into group 1: 10 patients underwent SIGS + Mitomycin C (MMC), and group 2: 10 patients underwent SST + MMC. The patients were followed-up over 2 years after surgery. Our outcome measures were: Postoperative intraocular pressure IOP, number of medications used, and postoperative complications. Results Twenty-four months postoperatively, the mean IOP was 13.78±2.05 mmHg in the SIGS group compared with preoperative IOP of 26.33±5.1 mmHg (P <0.001, paired t-test), and 14.38±4.56 mmHg in SST group compared with preoperative IOP of 30.13±7.51 mmHg (P <0.001, paired t-test). No significant differences in mean IOP between groups either preoperatively (P=0.15) or along follow-up (P=0.62 at last visit). The mean IOP drop from baseline was 12.56±5.00 mmHg (46.33±10.50%) in SIGS group and 15.75±8.22 mmHg (49.50±17.95%) in SST group (P=0.26). A significant decrease in the number of glaucoma medications was noted in the SIGSS group (P <0.001), in the SST group, the number decreased but was not statistically significant (P =0.120). Conclusion SIGS is comparable with SST in achieving long-term significant and maintained IOP reduction over up to 2 years, in addition to decreasing the number of antiglaucoma medications postoperatively. SIGS is recommended for surgical management of primary OAG as it has the advantage of being a faster, easier, less traumatic alternative to conventional SST with fewer complications.

Comparison of Outcomes of Phacoemulsification Combined with Endoscopic Cyclophotocoagulation, iStent, or Both in the Management of Open-Angle Glaucoma.

To compare outcomes of phacoemulsification combined with endoscopic cyclophotocoagulation (phaco/ECP), first generation iStent implantation (phaco/iStent), or both (phaco/iStent/ECP) in patients with open-angle glaucoma. A retrospective chart review was performed on patients at the University of Colorado Department of Ophthalmology. Outcomes included intraocular pressure (IOP), medication use, best corrected visual acuity (BCVA), and surgical complications were analyzed. Success was defined as IOP reduction of≥20% and/or reduction by at least one glaucoma medication. A total of 394 eyes were included in the study. There were 170 eyes (43.1%) in the phaco/ECP group, 175 eyes (44.4%) in the phaco/iStent group, and 49 eyes (12.4%) in the phaco/iStent/ECP group. The mean pre-operative IOP was 15.9mmHg for phaco/ECP, 15.8mmHg for phaco/iStent, and 15.2mmHg for phaco/iStent/ECP. At 24months, the mean IOP was 13.7mmHg (p<0.0001), 14.2mmHg (p=0.0001), and 13.0mmHg (p=0.0007), respectively. The mean pre-operative number of glaucoma medications was 2.0 for phaco/ECP, 1.4 for phaco/iStent, and 2.2 for phaco/iStent/ECP and at 24months post-surgery decreased to, 1.8 (p=0.011), 0.9 (p<0.0001), and 1.7 (p=0.01), respectively. The success rate at 24months was 54.4% for phaco/ECP, 75.3% for phaco/iStent, and 55.6% for phaco/iStent/ECP. Phacoemulsification when combined with ECP, iStent, or both, lowered IOP and glaucoma medication reliance at 24months. The success rate for phaco/iStent was significantly higher than phaco/ECP. When iStent was added to phaco/ECP, the success rate was higher at earlier postoperative visits compared to the phaco/ECP alone.

Sutureless versus conventional deep sclerectomy for management of open angle glaucoma

IntroductionTo compare sutureless deep sclerectomy to conventional deep sclerectomy regarding their lowering effect on intraocular pressure (IOP) in cases with open-angle glaucoma.MethodsThis is a prospective interventional randomized comparative study that included 60 eyes of 50 patients with open-angle glaucoma (OAG) who were indicated for surgical intervention. Patients were recruited from the glaucoma subspecialty clinic of the Cairo University teaching hospital and were divided into two groups: group A (underwent sutureless deep sclerectomy) and group B (underwent conventional deep sclerectomy).ResultsBoth surgeries showed significant reduction of IOP all through the study period: in group A, mean reduction was 71.37%, 53.35%, 50.3%, and 44.33% at 1st day, 1 month, 3 months, and 6 months respectively, and in group B, mean reduction was 57.62%, 40.63%, 37.41%, and 31.68% at 1st day, 1 month, 3 months, and 6 months, respectively. Comparison between percentage of reduction in both groups showed no statistically significant difference. Also, use of anti-glaucoma medications dropped significantly at 6 months postoperatively in both groups with no significant difference between the 2 groups. Regarding reported complications, 12.9% in group A and 10.3% in group B presented with non-serious complications. One month postoperatively, UBM detected non-functioning blebs in 6.4% of group A and 3.4% in group B. Other cases with non-functioning blebs were detected at 3 and 6 months postoperatively, and all cases were managed.ConclusionSutureless deep sclerectomy seems to be a safe and effective modification, with significant IOP reduction in POAG.

Treatment of open-angle glaucoma and ocular hypertension with preservative-free tafluprost/timolol fixed-dose combination therapy: 6 case reports and clinical outcomes

BackgroundTreatment of open angle glaucoma (OAG) and/or ocular hypertension (OHT) focuses on achievement of target intraocular pressure (IOP), with the objective of slowing disease progression. However, ocular surface health is an important consideration in the optimization of treatment. We report 6 patient cases in which enhanced IOP control was achieved following appropriate management of ocular surface inflammation and a therapeutic switch to the preservative-free (PF) tafluprost (0.0015%)/timolol (0.5%) fixed-dose combination (FC).Case presentationSix patient cases, aged 48–74 years, presented with OAG or OHT. Each patient had signs and symptoms of ocular surface disease (OSD). Cases 1–3 were each receiving maximal medical therapy for OAG; regimens comprising prostaglandin analogue (PGA), β-blocker, carbonic anhydrase inhibitor (CAI) and α-2 agonist agents (including treatments containing preservative agent). Cases 1 and 2 reported IOP values ≥23 mmHg in each eye, and wide IOP fluctuations were identified when reviewing patient data concerning case 3 (11–20 mmHg). Maximal therapy was ceased and PF tafluprost/timolol FC was initiated, after which the signs and symptoms of OSD were improved and IOP was reduced (≤18 mmHg for cases 1–3) and stabilized. Cases 4 and 5 were diagnosed with OAG and case 6 had OHT. Each had symptoms and signs of OSD and were treated with a preserved PGA monotherapy (latanoprost 0.005% or bimatoprost 0.03%). At presentation, IOP was 24 mmHg in both eyes (case 4), ≥18 mmHg (case 5) and ≥ 22 mmHg (case 6). Following a switch to the PF tafluprost/timolol FC, OSD symptoms were improved and IOP was 14 mmHg (both eyes; case 4), ≤14 mmHg (case 5) and 16 mmHg (both eyes; case 6).ConclusionsIn addition to IOP-lowering efficacy, approaches to the management of OAG and OHT should consider the impact of treatment tolerability and the susceptibility of these patients to OSD. The presence of ocular surface inflammation appears to be detrimental to adherence and therefore to the effectiveness of topical medications. Addressing OSD through the use of PF FC formations, such as the PF tafluprost/timolol FC, reduces exposure to potentially toxic agents and facilitates improvements in IOP control.

Long‐term result of combined ab externo Schlemm’s canal surgery and phacoemulsification in management of open angle glaucoma in cataract patients

AbstractPurposeTo evaluate the effectiveness of segmental Schlemm’s canal (SC) distension using Kumar’s Schlemm’s canal expander (SCE) in decreasing intraocular pressure (IOP) in cataract patients suffering from open angle glaucoma (OAG).MethodsBetween October, 2012 and March, 2020 in a prospective interventional case series study. SCE device, made from 0.04 mm thick medical grade stainless steel wire, having inner lumen diameter of 0.12 mm and outer – 0.2 mm, 4–5 mm long was implanted into SC ab externo after completion of cataract surgery of 59 patients (38 male and 21 female; average age – 75.47 ± 6.2 years) suffering from OAG. Outcome measures were IOP change, number of glaucoma medications pre‐ and postoperatively and complications. Success rates were evaluated using World Glaucoma Association guidelines. A paired t‐test was used for analysis. Results were significant when p less than 0.05.ResultsMean preoperative IOP was 28+/–4.7mmHg and mean number of medications – 2.4 ± 0.8. At 4 years mean IOP reduced by 27%+/–15.5% and was 20,4+/–4,9 (n=59; p=.0000006) use of medications reduced to 1 ± 1.2 (p = 0.0000001). Complete success was achieved in 24% (14/59) cases and partial – in 49% (29/59) respectively. Intraoperatively, microperforation occurred in 5 cases (8.5%). Postoperatively, 6 cases (10%) required YAG laser trabeculopuncture to control IOP. In these cases, one end of SCE was lying in anterior chamber angle without contact with intraocular structures. Postoperatively, specific complications related to SCE were rare. In one case the body of SCE ruptured TM because of extra pressure put on eye ball while inserting goniolens. Both ends of the expander were embedded in SC. Patient’s IOP was under control with one medication.ConclusionsCombined surgery phacoemulsification with intraocular lens implantation and SCE implantation in surgical management of OAG in cataract patients show significant reduction in IOP from the baseline and in hypotensive medication(s) use in long‐term period.

Comparative study to assess efficacy and safety of brinzolamide1% and timolol0.5% fixed combination eye drops versus dorzolamide2% and timolol0.5% fixed combination eye drops in management of open-angle glaucoma.

ABSTRACTAim and Objective:To compare the efficacy and safety of brinzolamide1% and timolol0.5% fixed combination eye drops versus dorzolamide2% and timolol0.5% fixed combination eye drops in the treatment of primary open-angle glaucomaDesign:Prospective, randomized, comparative, interventional studySetting:Tertiary eye care centre.Material and Method:The present study was a comparative study carried out on patients visiting OPD of Ophthalmology Department and diagnosed with primary open-angle glaucoma. Group 1 (n-30 BT) received brinzolamide1% and timolol0.5% fixed combination eye drops, and Group 2 (N-30 DT) patients received dorzolamide2% and timolol0.5% fixed combination eye drops. A complete ophthalmic examination was performed, including Goldmann applanation tonometry. IOP was measured twice daily (9 AM and 4 PM). The patients were evaluated at 2, 4, 8, and 12 weeks. IOP was measured at follow-up. Side effects and tolerability of both drugs were assessed, and patient preference for drugs was notedResults:Mean reduction in morning IOP was significantly more in Group 1 than in Group 2 at 8 weeks and 12 weeks (p < 0.05). Mean reduction in evening IOP was significantly more in Group 1 than in Group 2 at all follow-ups (p < 0.05)Conclusion:Brinzolamide1% + timolol0.5% fixed drug combination is more preferred and effective in lowering IOP than dorzolamide2% + timolol0.5% fixed drug combination in patients of primary open-angle glaucoma.

Отдаленные результаты сегментарной дилатация Шлеммова канала в хирургии открытоугольной глаукомы

Отдаленные результаты сегментарной дилатация Шлеммова канала в хирургии открытоугольной глаукомы

Efficacy and safety at 6 months of the XEN implant for the management of open angle glaucoma

The purpose of this study is to evaluate the efficacy and complications of the XEN implant as a solo procedure or in association with cataract surgery in patients with open angle glaucoma (OAG). All patients who received a XEN implant between June 2017 and June 2018 were included in the study. The primary and secondary outcomes were: the reduction of the intraocular pressure (IOP) at 6 months postoperatively, the decrease of the glaucoma medications 6 months after surgery, the clinical success rate (eyes (%) achieving ≥20% IOP reduction on the same or fewer medications without secondary surgical intervention), the frequency and type of postoperative interventions as well as the complication rate. We included one hundred and seven eyes from 97 patients with primary OAG (79%), or secondary OAG (21%). Seventy-seven patients (72%) received a standalone XEN implantation and 30 (28%) underwent XEN implantation combined with phacoemusification. The IOP decreased from 20.4 mm Hg ± 6.4 preoperatively to 15.4 mm Hg ± 5.3 six months after the surgery, which represented a reduction of 24.5% (P = 1.4.10−7). It was associated with a lowering of glaucoma medications from 2.8 ± 1.0 preoperatively to 0.6 ± 1.0 six months postoperatively (P = 3.6.10−34). The clinical success rate was 67.2% six months after the surgery. The most frequent complications were: IOP spikes >30 mmHg (16.8%), improper position or angled drain (14.0%) and transient minimal hyphema (<1 week) (11.2%). During the follow-up, the needling was required in 34.6% of cases and a total of 10 eyes (9.4%) required a new glaucoma surgery. To conclude XEN implantation appears to be an effective short- and mid-term surgical technique to control IOP in OAG with a low risk of complication. However postoperative maneuvers were frequently required to maintain efficiency.

Screening, Diagnosis, and Management of Open Angle Glaucoma

Glaucoma is the most common form of irreversible blindness in the world, and second only to cataract among all causes of blindness. There is still no universally agreed-upon definition of glaucoma, and as such, it remains a condition for which there are differing views on the classification of individuals within the continuum of suspicion through diagnosis. Regardless, there appears to be consensus that glaucoma refers to a group of diseases that manifest as a characteristic progressive optic neuropathy and retinal ganglion cell loss that eventually leads to a permanent loss of visual field.&#x0D; Glaucoma is a major public health issue because individuals are typically asymptomatic until end stages of the disease when the associated vision loss is significant and irreversible. Studies have shown that the prevalence of undetected glaucoma is as high as 50% even in high income areas including North America and Australia, increasing to 90% in middle and low income areas such as Asia and Africa. This is at least in part a result of inadequate screening tools and strategies to detect this asymptomatic disease: without more individuals accessing routine eye examinations, glaucoma will continue to go undetected.&#x0D; Vision loss from glaucoma imposes significant societal and economic burdens that increase with disease severity: the direct costs of vision loss from glaucoma exceed $300 million annually in Canada, and approach $2 billion across North America.

Management of the open angle glaucoma in patients with central/hemicentral retinal vein occlusions.

To prospectively assess the cumulative prevalence and management of open angle glaucoma (OAG), including primary open angle glaucoma (POAG) with high and normal-pressure, as well as pseudoexfoliative glaucoma (PEXG), in patients with central/hemicentral retinal vein occlusions (RVOs) over a 3-year follow-up period. The study encompassed 57 patients with unilateral acute central/hemicentral RVOs. A complete ophthalmic examination of both eyes was undertaken for all patients. Patients with OAGs associated with central/hemicentral RVOs were treated with the current ocular hypotensive medications used worldwide and/or surgery and aimed to reduce the intraocular pressure (IOP) by 30% from baseline values for the 3 OAG forms existing in our series. The cumulative prevalence of OAG and the efficacy of treatment were evaluated. OAG was observed in 3 clinical forms, namely, POAG with increased IOP in 4 patients, POAG with normal IOP in 3 patients, and PEXG in 3 patients. The cumulative prevalence of OAG was 19.6% (95%CI: 8.7-30.5). Using available ocular hypotensive medications (8 patients) and trabeculectomy (2 patients), the IOP decreased significantly from 24.3±4.36 mm Hg to 16.55±2.85 mm Hg, a reduction of 31.89% compared with baseline values. Glaucoma progression was not detected in any of the cases. The high value of the cumulative prevalence of OAG is a risk factor for the development of venous occlusion. The treatment of glaucoma prevented its progression over a follow-up period of 3y.

Association Between Lamina Cribrosa Defects and Progressive Retinal Nerve Fiber Layer Loss in Glaucoma

Certain features of the lamina cribrosa may be associated with increased risk of glaucoma progression. To compare the rates of retinal nerve fiber layer (RNFL) thinning in patients with open-angle glaucoma with or without lamina cribrosa (LC) defects and to evaluate factors associated with the rate of glaucoma progression in eyes with LC defects. This longitudinal cohort study designed in September 2017 and conducted at a tertiary glaucoma center in California included 51 eyes of 43 patients with LC defects and 83 eyes of 68 patients without LC defects followed up for a mean (SD) of 3.5 (0.8) years from April 2012 to May 2017. Focal LC defects were detected using swept-source optical coherence tomographic images. All participants underwent visual field testing and spectral-domain optical coherence tomography for RNFL thickness measurements every 6 months. Univariate and multivariable random-effects models were used to compare the rate of local and global RNFL loss. The mean (95% CI) age at baseline for individuals with LC defects was 69.5 (65.4 to 73.6) years, and for those without LC defects, it was 69.6 (67.2-72.0) years; 18 individuals (41%) with LC defects and 35 individuals (51%) without LC defects were men; 6 individuals (14%) with LC defects and 17 individuals (25%) without were African American. The mean (95% CI) rate of global RNFL loss in eyes with LC defects was 2-fold faster than that in eyes without LC defects (-0.91 [-1.20 to -0.62] vs -0.48 [-0.65 to -0.31] μm/y; difference, -0.43 [-0.76 to -0.09] μm/y; P = .01). The rate of RNFL thinning was faster in the LC defect sectors than that in the unaffected sectors (difference, -0.90 [95% CI, -1.68 to -0.12] μm/y, P = .02). Thinner corneal thickness was the only factor that was associated with a faster rate of RNFL loss in eyes with LC defects (β2 = -0.09 [95% CI, -0.14 to -0.04], P = .001). No association was found between mean intraocular pressure during follow-up and the mean rate of RNFL thinning in eyes with LC defects (β2, -0.05 [95% CI, -0.17 to 0.06], P = .36). These data suggest that LC defects are an independent risk factor for RNFL thinning and that glaucoma progression may correspond topographically to the LC defect location. Thinner corneal thickness in eyes with LC defects was associated with faster further glaucoma progression. In the management of open-angle glaucoma, LC findings may inform the likelihood and rate of glaucoma progression.

Оценка безопасности и эффективности обратного циклодиализа ab interno с имплантацией супрацилиарного металлического имплантата собственной конструкции в хирургическом лечении открытоугольной глаукомы у пациентов с катарактой

Оценка безопасности и эффективности обратного циклодиализа ab interno с имплантацией супрацилиарного металлического имплантата собственной конструкции в хирургическом лечении открытоугольной глаукомы у пациентов с катарактой

Selective Trabeculoplasty in the Management of Open Angle Glaucoma: Retrospective Analysis at 1 Year

Selective Trabeculoplasty in the Management of Open Angle Glaucoma: Retrospective Analysis at 1 Year

Microinvasive Invasive Glaucoma Surgery: Principles Shaping Glaucoma Surgery for the Future

Over the last half century, open-angle glaucomamanagement has revolved mainly around topicalmedical treatment with or without lasertrabeculoplasty, with gold standard trabeculectomykept back for patients with advanced and progressingglaucoma. Keeping in mind the possible complicationsassociated with trabeculectomy and glaucoma valves,1these are usually kept for late glaucoma treatmentalgorithm. Development of new topical medicationshas actually reduced the rate of trabeculectomyremarkably.

Micropulse diode laser trabeculoplasty in Nigerian patients.

IntroductionThe term micropulse laser trabeculoplasty suggests that only a fraction of the laser power is applied to the trabeculum to effect pressure lowering. It has not yet been exclusively used in Negroes, and we wish to report on our experience in Nigerian patients.MethodsThe study design is a retrospective chart review of our patients at the Rachel Eye Center in Abuja. The 810 diode Optos FastPulse laser was used to apply 34 cycles of treatment to 30 eyes of 16 individuals. Patients were selected based on the failure of maximal medical therapy. One patient had two extra rounds of treatment, while two patients were treated in only one eye. The pressure change at 1 hour after the treatment was analyzed. Patients were followed up for a mean period of 160 days with continuous monitoring of pressure changes. Patients’ original therapy was not disturbed.ResultsPostlaser immediate drop in intraocular pressure (IOP) averaged 3.2 mmHg (CI 1.6–4.7, P<0.0001) representing 17.2% drop from baseline prelaser IOP. The drop in IOP was sustained over varying periods, from a few weeks to several months. There was a temporary spike in three instances. No serious side effects were noted.ConclusionMicropulse diode laser trabeculoplasty is a useful adjunct in the management of open-angle glaucoma in Nigerians. This corroborates the findings of other researchers in western populations.

Influence on intraocular pressure of anti-inflammatory treatments after selective laser trabeculoplasty

Selective laser trabeculoplasty (SLT) is an effective and safe procedure to lower intraocular pressure (IOP) in the management of open-angle glaucoma. The post-laser inflammatory reaction could be positively implicated in SLT efficacy and the relevance of postoperative use of topical anti-inflammatory remains controversial. The goal of this study is to determine the effect of various anti-inflammatory treatments on intraocular pressure and on side effects following SLT. A prospective, randomized, double-blind study with a control group was conducted. Ninety-six eyes of 67 patients with primary open-angle glaucoma who underwent SLT were enrolled in this study between March 2009 and March 2012. Eyes recruited in the study were randomized to receive either prednisolone acetate 1%, diclofenac 0.1% or a placebo. The 3 treatments were administered 4 times a day for 5 days following SLT. The intraocular pressures were measured at regular intervals during the 6-months follow-up period. Side effects were also evaluated with a questionnaire as well as with the ocular exam. The analysis of the relative IOP decrease over the 6-months period revealed a significant difference between the time points of follow-up (P<0.0001), but no group effect (P=0.2980). No significant difference regarding anterior chamber inflammation and discomfort was observed between the 3 groups. There was no difference in intraocular pressure reduction, intraocular inflammation or ocular discomfort post-SLT when comparing the 3 treatment modalities.

Lasers in Open Angle Glaucoma

Lasers have been used in open angle glaucoma for more than 40 years and have grown in importance in recent years. This article reviews the latest research and trends in the use of lasers in the management of open angle glaucoma.

Tafluprost: A Systematic Review of Pharmacology and Therapeutic Potential in the Management of Glaucoma and Ocular Hypertension

Glaucoma is the second most common cause of blindness worldwide. Treatment of glaucoma mainly aims at improving the visual loss and hence quality of life. Conventional drugs used are adrenoreceptor agonists, carbonic anhydrase inhibitors, β-adrenergic receptor antagonists, anticholinergics and prostaglandin (PG) analogues. PG analogues have taken the centre stage for the management of open-angle glaucoma (OAG) due to their better efficacy, tolerability, low-cost and once-a-day dosing. After Latanoprost, Travoprost and Bimatoprost, Tafluprost is a new PGF 2α receptor agonist that has recently been approved for use in OAG and ocular hypertension. It is available in both preserved and preservative-free (PF) formulation. Its PF formulation offers an extra advantage to patients who develop adverse effects due to preserved ocular hypotensives. Various animal and human studies have demonstrated comparable intraocular pressure (IOP)-lowering efficacy and better tolerability of preserved and PF tafluprost in glaucomatous patients to the conventional anti-glaucoma drugs. This review elucidates the available evidence on efficacy and safety of this drug after analysing preclinical and clinical studies of this drug conducted across the world in OAG and ocular hypertension. Pubmed, Cochrane database, Medscape, Google and clinicaltrial.org were searched for terms like tafluprost, ocular hypertension and open-angle glaucoma. Relevant journal articles were chosen to provide the necessary information.